Verbeek Wieke H M, von Blomberg B Mary E, Scholten Petra E T, Kuik D Joop, Mulder Chris J J, Schreurs Marco W J
Department of Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands.
Am J Gastroenterol. 2008 Dec;103(12):3152-8. doi: 10.1111/j.1572-0241.2008.02213.x.
In refractory celiac disease (RCD) type II, a phenotypically aberrant (CD7+ CD3- CD4/8-cytoplasmicCD3+) intraepithelial lymphocyte (IEL) population is present, and 50-60% of these patients develop enteropathy-associated T-cell lymphoma (EATL). TCRgammadelta+ IELs play an important role in mucosal repair, homeostasis, and tumor surveillance. Recently, human small intestinal TCRgammadelta+ IELs were shown to have regulatory potential in uncomplicated celiac disease (CD).
In the present study, we investigated whether TCRgammadelta+ IELs are decreased in RCD II, providing a possible explanation for persisting mucosal damage and inflammation, and the emergence of aberrant T cells with clonal expansion to EATL.
Multiparameter flow cytometric immunophenotyping was performed on IELs isolated from fresh small bowel biopsy specimens of relatively large distinct CD patient and control groups (N = 87).
A significantly lower percentage of TCRgammadelta+ IELs was found in RCD II as compared to all other CD groups. In contrast, in uncomplicated CD patients significantly more TCRgammadelta+ IELs were found than in controls. Overall, there is a clear negative relation between TCRgammadelta+ IELs and aberrant IELs. Interestingly, TCRgammadelta+ IELs increase again in RCD II after effective therapy.
The observed negative relation between TCRgammadelta+ and aberrant IELs, along with their known regulatory capacity in uncomplicated CD, implies that TCRgammadelta+ IELs may play a crucial role in mucosal repair, regaining homeostasis and possibly even tumor surveillance. These cells may be important markers, in addition to the aberrant T cells, to differentiate between disease categories and to evaluate the effectiveness of therapeutic strategies.
在II型难治性乳糜泻(RCD)中,存在表型异常的(CD7 + CD3 - CD4/8 - 细胞质CD3 +)上皮内淋巴细胞(IEL)群体,并且这些患者中有50 - 60%会发展为肠病相关T细胞淋巴瘤(EATL)。TCRγδ + IEL在黏膜修复、内环境稳定和肿瘤监测中起重要作用。最近,人类小肠TCRγδ + IEL在非复杂性乳糜泻(CD)中显示出具有调节潜能。
在本研究中,我们调查了RCD II中TCRγδ + IEL是否减少,这可能为持续的黏膜损伤和炎症以及异常T细胞克隆性扩增发展为EATL提供一种解释。
对从相对较大且不同的CD患者和对照组(N = 87)的新鲜小肠活检标本中分离出的IEL进行多参数流式细胞术免疫表型分析。
与所有其他CD组相比,RCD II中TCRγδ + IEL的百分比显著降低。相反,在非复杂性CD患者中发现的TCRγδ + IEL明显多于对照组。总体而言,TCRγδ + IEL与异常IEL之间存在明显的负相关。有趣的是,有效治疗后RCD II中的TCRγδ + IEL再次增加。
观察到的TCRγδ +与异常IEL之间的负相关,以及它们在非复杂性CD中已知的调节能力,意味着TCRγδ + IEL可能在黏膜修复、恢复内环境稳定甚至可能在肿瘤监测中起关键作用。除了异常T细胞外,这些细胞可能是区分疾病类别和评估治疗策略有效性的重要标志物。